When CAF01 was applied as an adjuvant for the tuberculosis vaccine known as Hybrid 1 (H1), carrying the hybrid protein of Early Secretory Antigenic Target (ESAT) and Antigen 85B, it induced a strong and long-lasting (3 years) CD4+ T-cell response in a dose-dependent manner [53]. Here, CD4 is linked to tuberculosis.